Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label booster safety trial of VLPCOV-04 in healthy adults
jRCT2051230178Phase 3Completed
- Sponsor
- VLP Therapeutics Japan
- Start
- Feb 2024
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of VLPCOV-04 in coronavirus disease 2019 (COVID-19), sponsored by VLP Therapeutics Japan. Primary endpoints: Solicited local adverse events through Day 7, Solicited systemic adverse events through Day 7 and 1 more. Started Feb 2024; status: completed.
02
Drugs
VLPCOV-04
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2051230178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051230178.